Senators Seek Probe of Cyclospora Outbreak Response
Three senators asked HHS's inspector general to examine how FDA and CDC staffing and policy changes affected the summer multistate outbreak.
Updated on Nov. 19, 2026 in Health

Live Poll
Do you trust federal agencies to keep food safe?
Senators Patty Murray, Jeanne Shaheen, and Tammy Baldwin asked HHS Inspector General Marcia Bell to investigate the summer 2026 multistate Cyclospora outbreak, which was linked to contaminated lettuce from Mexico. Separately, Gilead Sciences signed licensing agreements with three generic drug manufacturers covering its experimental antiviral obeldesivir in 127 low- and middle-income countries.
Why it matters
The senators allege that illegal staffing cuts at the FDA and CDC over the last 18 months contributed to delayed recalls and inspections linked to the outbreak. Gilead's agreements are intended to position the company to supply obeldesivir if it demonstrates benefit and gains regulatory approval.
The senators' letter cites an 18-month window of alleged staffing cuts at the FDA and CDC as the period under review. Gilead's agreements cover 127 countries, but the extraction does not say when generic versions would reach patients.
The players
Department of Health and Human Services
The federal department whose inspector general received the senators' request and which oversees the FDA and CDC.
Food and Drug Administration
The federal agency responsible for regulating food safety and drug approvals, whose staffing and recall response is under review.
Centers for Disease Control and Prevention
The federal public health agency that tracks multistate outbreaks such as the summer Cyclospora outbreak.
Gilead Sciences
A biopharmaceutical company that developed the experimental antiviral obeldesivir and signed the generic licensing agreements.
The details
The senators' letter asks the inspector general to examine how personnel and policy changes at the FDA and CDC affected the response to the Cyclospora outbreak. Gilead is evaluating obeldesivir as post-exposure prophylaxis for Bundibugyo Ebola, with a phase 3 trial underway in the Democratic Republic of Congo.
Timeline
Summer 2026: Multistate Cyclospora outbreak occurs.
Last 18 months: Alleged illegal staffing cuts at FDA and CDC take place.
This week: Senators send the investigation request letter.
Yesterday: Gilead announces licensing agreements with three generic manufacturers.
Health Landscape
Cyclospora outbreaks traced to produce, including the 2018 McDonald's salad cases, have repeatedly tested federal food-safety monitoring. The current request asks whether recent agency changes weakened that system, while Gilead's licensing deals reflect a separate push to widen access to emerging antivirals in poorer countries.
Consumers who eat raw lettuce should check for recalls before purchasing, since the outbreak was linked to Mexican lettuce. Access to obeldesivir would depend on future regulatory approval and generic production, which the agreements do not guarantee on any timeline.
The takeaway
Food-safety and drug-access decisions both depend on agency capacity, so staffing levels at the FDA and CDC matter to outcomes readers feel directly. Watch for the inspector general's response to see whether the outbreak review extends to those staffing decisions.
Further reading
Explore more in Health — General for context on outbreak response and drug access.
Source note: This article includes information reported by Umn.
Live Poll
Do you trust federal agencies to keep food safe?






